The ubiquitin pathway contains a plethora of novel therapeutic targets. Progenra's ability to discover novel structures with its high throughput assays has created several opportunities for establishing partnerships with other companies.
Recognizing that 1) there is still much to discover in the ubiquitin-proteasome pathway and 2) the need for rigorous validation of ubiquitin pathway targets, Progenra encourages academic laboratories to contact us with potential collaborative projects. Progenra is especially interested in prospective collaborations with translational potential.
We are pleased to have collaborations with leading national and international academic institutions including: